I like the technology that they have regarding mamography. The fact that it can be used in conjunction with x-ray and ultrasound to assist in differentiating malignant from benign lesions is great. This will reduce the great number of invasive biopsies performed which later prove to be negative. However the technology is in the process of being approved by the FDA and if it does pass FDA approval I can see the pps skyrocketing.
Does anybody know if you can find out the probability of a product being approved by the FDA? How long do these tests take? and how much can they affect the pps?
I also cannot read charts if someone wants to take a look at this one and let me know what you think.....
FORT LAUDERDALE, Fla., Feb 01, 2005 /PRNewswire-FirstCall via COMTEX/ -- Imaging Diagnostic Systems, Inc. (OTC Bulletin Board: IMDS) announced today that it has sold a CT Laser Mammography system to be installed at Al Salama Hospital in Abu Dhabi, United Arab Emirates. The installation will mark the third CT Laser Optical Mammography system sold in the region. (Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )
Al Salama Hospital, established in 1979, is a member of the International Hospital Association and an accredited certified teaching hospital. They received the Shiekh Khalifa Excellence award in 2004 for providing medical services in accordance with the highest caliber of international standards.
"Al Salama is a highly regarded hospital that could open many doors and potential sales in my country. We are planning to exhibit at the 2005 Arab Health Conference and Al Salama may be a great place for serious customers to see the revolutionary CTLM system in action," stated IDSI distributor, Mr. Vassileios Avdos, Managing Director of Abu Dhabi International Medical Services.
Tim Hansen, IDSI CEO, commented, "We are pleased with the general acceptance of our new technology in the region. We are also proud to be associated with Al Salama Hospital in the important work of helping to manage breast cancer care."
The CTLM(R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000- 13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM(R) system to be used as an adjunct to mammography.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company's filing with the Securities Exchange Commission.
Investor Relations: Rick Lutz 404-261-1196 email@example.com
SOURCE Imaging Diagnostic Systems, Inc.
-------------------- grasshopper Posts: 268 | From: LA | Registered: Dec 2004
| IP: Logged |